Maravai Lifesciences Holdings, Inc. ((MRVI)) has held its Q4 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Maravai Lifesciences’ latest earnings call struck a cautiously upbeat tone, as management framed 2025 as the year of operational reset and 2026 as the year of recovery. Executives highlighted a sharp swing back to positive adjusted EBITDA in the fourth quarter, substantial cost savings, and solid product momentum, while openly acknowledging heavy GAAP losses, leverage, and lumpy demand.
Revenue Beat and Underlying Q4 Growth
Maravai reported full‑year 2025 revenue of $185.7 million, edging past guidance by about $0.7 million and signaling stabilizing demand. Fourth‑quarter revenue came in at $49.9 million and, excluding a one‑time surge of COVID‑related CleanCap sales in the prior‑year quarter, underlying Q4 sales grew a healthy 18% year over year.
Return to Positive Adjusted EBITDA
The company delivered positive adjusted EBITDA of $0.536 million in the fourth quarter, its first positive print in four quarters and a key milestone in the turnaround narrative. That result marked an improvement of roughly $11 million versus the third quarter and a sharp swing from the $1.1 million adjusted EBITDA loss recorded in the year‑ago period.
Cost Cutting Exceeds Ambitious Targets
Management emphasized that restructuring and cost‑saving actions are running ahead of plan, with annualized savings now estimated above $65 million versus a prior target of more than $50 million. The company captured about $3 million of savings in the third quarter and roughly $8 million in the fourth, setting a leaner cost base heading into 2026.
Cygnus Delivers Steady Growth and Rich Margins
Cygnus, Maravai’s high‑margin analytical business, continued to anchor profitability with resilient growth and exceptional margins. Fourth‑quarter revenue rose 4% year over year to $15.3 million, generating adjusted EBITDA of $10.2 million and a 66.7% margin, while full‑year revenue reached $66 million with a robust 67% adjusted EBITDA margin.
TriLink’s Mixed Picture: Decline Headline, Growth Underneath
TriLink posted fourth‑quarter revenue of $34.6 million, down 17% year over year on the surface due to tough comparisons from elevated COVID CleanCap demand. Stripping out $14.3 million of such sales in the prior‑year quarter, base TriLink revenue actually grew 25% and generated $0.936 million in adjusted EBITDA, hinting at a recovering core business.
Product Pipeline and Commercial Traction Build Momentum
Management spotlighted several growth vectors, including ModTail, which launched in the second half of 2025, generated over $0.5 million last year and has already exceeded that level in 2026 bookings. The mRNAbuilder platform has processed about 70 orders to date, while the new IVT kit booked more than 100 orders in its first weeks and GMP enzymes have over $1.2 million of orders in hand for 2026.
Guidance Signals Turnaround in 2026
Maravai’s 2026 outlook calls for revenue of $200 million to $210 million, implying 8% to 13% growth and a return to meaningful top‑line expansion. Management expects full‑year adjusted EBITDA of $18 million to $20 million, around 1,200 basis points of gross margin expansion, lower operating expenses and, importantly for investors, a move to positive adjusted EBITDA and positive cash flow.
Balance Sheet Actions and Leverage Concerns
The company closed 2025 with $216.9 million in cash and $294.2 million in long‑term debt, then executed a voluntary $50 million debt repayment in the first quarter of 2026 to cut interest costs. Still, management acknowledged that leverage and fourth‑quarter cash burn, with $22.8 million used in operations including $3.6 million of restructuring, remain important watchpoints.
Legal and Control Overhangs Eased
On the governance front, Maravai completed remediation of previously identified internal control material weaknesses, aiming to restore investor confidence in its financial reporting framework. The company also reported that securities class action lawsuits in U.S. District Court were dismissed in full, removing a key legal overhang.
Large GAAP Losses Mask Operational Progress
Despite operational gains, GAAP numbers remained deeply negative, with a fourth‑quarter net loss before noncontrolling interest of $63 million, wider than the $46.1 million loss a year earlier. That result included a $25.8 million noncash intangible impairment and $12.1 million of noncash restructuring charges, while full‑year GAAP net loss narrowed modestly to $230.8 million from $259.6 million.
Full‑Year Adjusted EBITDA Still in the Red
For 2025 as a whole, adjusted EBITDA remained negative at $31.2 million, a modest improvement from the $35.9 million loss in 2024 but still signaling an unprofitable year on a non‑GAAP basis. Management framed the fourth‑quarter inflection to positive adjusted EBITDA as the starting point for sustained improvement, rather than a signal that the turnaround is complete.
EPS Trends Reflect Pressure from Charges
Loss per share also showed mixed progress, with fourth‑quarter basic and diluted GAAP EPS at a loss of $0.24 versus a $0.18 loss a year earlier, weighed down by impairments and restructuring. Adjusted EPS in the quarter improved to a $0.04 loss from a $0.06 loss, but the full‑year adjusted fully diluted EPS loss widened to $0.29 compared with a $0.10 loss in the prior year.
Persistent Leverage and Cash Flow Risks
Investors were reminded that Maravai still carries substantial leverage, with long‑term debt near $300 million at year‑end before the voluntary repayment. Cash used in operations in the fourth quarter was $22.8 million, reinforcing that balance‑sheet repair and free‑cash‑flow generation remain critical priorities even as adjusted EBITDA improves.
Order Lumpiness Complicates Forecasting
Management cautioned that the business continues to exhibit meaningful lumpiness, with an average order cycle of roughly six months and demand tied to customer program progression. While visibility has improved thanks to higher early‑period orders, these dynamics can drive quarter‑to‑quarter volatility and make precise forecasting more challenging.
TriLink’s Full‑Year Weakness Shows Recovery Still in Early Stages
On a full‑year basis, TriLink’s performance underscored that parts of the portfolio are still climbing back from the post‑COVID reset, with annual revenue declining 8% when excluding high‑volume CleanCap sales. TriLink’s full‑year adjusted EBITDA was a loss of $23.1 million, signaling that further scaling and efficiency gains are needed to unlock consistent profitability.
2026 Guidance Paints a Clearer Recovery Path
Looking ahead, management’s 2026 guidance outlined a more confident recovery trajectory, calling for revenue of $200 million to $210 million and adjusted EBITDA of $18 million to $20 million, a roughly $50 million swing from 2025. The plan assumes notable gross margin expansion, double‑digit cuts in operating costs and interest expense of $15 million to $17 million, underpinned by continued cost discipline and rising contribution from newer products.
Maravai’s earnings call sketched a story of early but tangible progress toward a 2026 profitability comeback, powered by disciplined cost cuts, strong Cygnus margins and emerging product traction at TriLink. Yet investors must weigh that optimism against sizable GAAP losses, leverage and order volatility, making execution over the next few quarters critical to validating the turnaround thesis.